bet proteins

Molibresib (GSK525762) 是一种 BET 溴结构域抑制剂，IC50为32.5在42.5 nM 之间。

CF53 是一种高效、选择性、可口服的 BET 抑制剂，对 BRD4 BD1 的 Ki 值为 <1 nM，Kd 值为 2.2 nM，IC50 值为 2 nM；CF53 对 BRD2，BRD3，BRD4 和 BRDT BET 蛋白的 BD1 和 BD2 两个结构域都有高亲和性，对其选择性远高于非含溴结构域 BET 蛋白。CF53 在体外和体内都具有显著的抗肿瘤活性。

ZEN-3411 是一种可口服且具有高效性的 BET 抑制剂，抑制 BRD4(BD1)，BRD4(BD2) 和BRD4(BD1BD2)，抑制过度产生 BET 蛋白的肿瘤细胞的生长。

Hexamethylene bisacetamide 抑制 BET Bromodomain 蛋白。

Birabresib (MK-8628) 是一种 BRD2 3 4抑制剂，IC50值为 92 到 112 nM 之间，具有潜在的抗肿瘤活性。

BET-BAY 002 S enantiomer为BET-BAY 002的S型对映异构体，属于BET小分子抑制剂。

Molibresib besylate (GSK 525762C) 是一种具有选择性和高效性的溴结构域和末端外 （BET） 蛋白家族抑制剂，具有潜在的抗癌活性，可用于研究难治性血液系统恶性肿瘤疾病。Molibresib besylate 产生活性氧 （ROS），增强 ATM 激活。

PROTAC BET degrader-2 is a highly potent degrader of Bromodomain and Extra-Terminal (BET) proteins, with an IC50 of 9.6 nM.

(R)-BAY1238097是BAY1238097的R-异构体，其活性相对较低。BAY1238097 是一种针对 BET 蛋白与组蛋白结合的高效选择性抑制剂，在各种急性髓性白血病（AML）和多发性骨髓瘤（MM）模型中显示出显著的抗增殖作用。其高活性是通过下调 c-Myc 水平并随后调节其下游转录组实现的。

(S,R,S)-AHPC-Me dihydrochloride, also known as VHL ligand 2 dihydrochloride, is a chemical compound utilized in the synthesis of ARV-771. ARV-771, a BET PROTAC degrader relying on von Hippel-Landau (VHL) E3 ligase, demonstrates potent degradation of BET protein in castration-resistant prostate cancer (CRPC) cells, with a DC50 of less than 1 nM. This compound serves as the VHL ligand, specifically the (S,R,S)-AHPC-based VHL ligand, that facilitates the recruitment of von Hippel-Lindau (VHL) protein.

PROTAC BET Degrader-3 is a potent degrader of BET proteins based on the PROTAC (PROteolysis TArgeting Chimera) technology.

PROTAC BRD2 BRD4 degrader-1 (compound 15) serves as a potent, selective degrader of BET proteins BRD4 and BRD2, achieving rapid, reversible, and unexpectedly selective elimination of BRD4 and BRD2 compared to BRD3. Its efficacy in suppressing solid tumors manifest with minimal cytotoxic effects. This compound comprises a BET inhibitor, a connecting linker, and thalidomide as the ligand for cereblon (CRBN) cullin 4A[1].

Thalidomide-NH-C4-NH2 TFA (compound 29c) is a conjugate consisting of an E3 ligase ligand-linker, incorporating the Thalidomide-based cereblon ligand and a linker moiety. This compound, Thalidomide-NH-C4-NH2 TFA, is utilized as a component in PROTAC BRD2 BRD4 degrader-1, which is a highly potent and selective degrader targeting BET proteins BRD4 and BRD2[1].

GSK2820151 is an orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential antineoplastic activity.

RX-37 is a potent BET inhibitor with Ki values of 3.2-24.7 nM for BRD2, BRD3 and BRD4. RX-37 demonstrates high selectivity over other non-BET bromodomain-containing proteins. RX-37 potently and selectively inhibits cell growth in human acute leukemia cell

Mivebresib (ABBV-075) 是一种有效的，口服活性的溴结构域和末端结构域 (BET) 抑制剂，结合BRD4的Ki 值是 1.5 nM。

GSK097 is a highly potent and selective inhibitor of the second bromodomain (BD2) found in bromodomain and extra-terminal domain (BET) proteins. It exhibits a remarkable 2000-fold selectivity for BD2 over BD1, as indicated by BRD4 data. Additionally, GSK097 demonstrates solubility of over 1 mg mL in FaSSIF media.

BET bromodomain inhibitor 1 is an orally active, selective inhibitor of bromodomain and extra-terminal (BET) proteins. It specifically inhibits BRD4 with an IC50 of 2.6 nM. Additionally, BET bromodomain inhibitor 1 demonstrates high affinities towards BRD2(2), BRD3(2), BRD4(1), BRD4(2), and BRDT(2) with Kd values of 1.3 nM, 1.0 nM, 3.0 nM, 1.6 nM, and 2.1 nM, respectively. This compound exhibits anti-cancer activity.

SIM1 is a potent and selective trivalent PROTAC®Degrader based on BET bromodomain inhibitors linked to a Von Hippel Lindau (VHL) ligand via branched linkers. SIM1 degrades all BET family proteins with a preference for BRD2 (DC50values = 0.7 nM, 1.1 nM and 3.3 nM for BRD4, BRD2 and BRD3, respectively). SIM1 degrades BRD2 more significantly and rapidly than BRD3 and BRD4, and degrades BET proteins with a higher potency than a bivalent degrader. SIM1 also decreases protein levels for Myc and HMOX1 and induces apoptosis in prostate cancer cells.

GSK1324726A (I-BET726) 是一种选择性有效的BET 蛋白抑制剂，高亲和力结合到BRD2、BRD3和BRD4，IC50值分别为 41 nM、31 nM 和 22 nM。

ET-JQ1-OH 是一种等位基因特异性的 BET 抑制剂。

I-BET282E 是八种 BET bromodomains 泛抑制剂，对其他代表性含溴代烷的蛋白质表现出选择性。I-BET282E 能够作用于 8 种 BRD2 (BD1 BD2), BRD2 (BD1 BD), BRD3 (BD1 BD), BRD4 (BD1 BD) ，他们的 pIC50值为 6.4-7.7。

GSK789 is a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins.

SB-284851-BT 是一种 BRD4 p38α BRDT 抑制剂。SB-284851-BT 抑制BRD4-BD1(IC50=1.7 µM)、p38α(Kd=0.47 nM)、BRDT(1) (IC50=18 µM) 和BRD4(1) (IC50=3.7 µM)。SB-284851-BT 通过抑制p38α以减少IL-8的产生，抑制BRD4以下调癌症的c-Myc 和NF-κB 基因通路。SB-284851-BT 能与溴结构域和超末端结构域 (BET) 结合。